Reference number: 51
Description:
EMA Committee for Orphan Medicinal Products. Public summary of opinion on orphan designation Canakinumab for the treatment of tumour necrosis factor receptor-associated periodic syndrome (Rep. No. EMA/COMP/663189/2012). (n.d.). Retrieved April 18, 2013, from http://www.ema.europa.eu/docs/enGB/documentlibrary/Orphan_designation/2012/12/WC500136400.pdf